Aurobindo Pharma gets US FDA nod for anti-HIV tablets

The company's Ritonavir tablets in the strength of 100 mg got the health regulator's tentative approval

Aurobindo Pharma
Aurobindo Pharma
Press Trust of India New Delhi
Last Updated : Feb 27 2016 | 8:35 PM IST
Drug firm Aurobindo Pharma has received tentative approval from the US health regulator for its Ritonavir tablets used for treatment of human immunodeficiency virus infection.

The United States Food and Drug Administration (US FDA) has given tentative approval to Aurobindo Pharma's Ritonavir tablets in the strength of 100 mg, FDA said on its website.

Established in 1986, Aurobindo Pharma is present in semi-synthetic penicillins and therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 27 2016 | 8:07 PM IST

Next Story